Search Results - "DeVore, R. F."

Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group by SCHILLER, Joan H, ADAK, Sudeshna, CELLA, David, DEVORE, Russell F, JOHNSON, David H

“…To determine the efficacy of topotecan in combination with standard chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer…”
Get full text

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer by Heymach, J. V., Johnson, D. H., Khuri, F. R., Safran, H., Schlabach, L. L., Yunus, F., DeVore, R. F., De Porre, P. M., Richards, H. M., Jia, X., Zhang, S., Johnson, B. E.

“…Background: R115777 (tipifarnib, Zarnestra™) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction…”
Get full text

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study) by Choy, H, Devore, 3rd, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, Johnson, D H

“…We conducted a prospective phase II study to determine the response rate, toxicity, and survival rate of concurrent weekly paclitaxel, carboplatin, and…”
Get more information

Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer by Choy, H, Akerley, W, DeVore, 3rd, R F

“…Combination chemotherapy plus radiation therapy for non-small cell lung cancer has several theoretical advantages: the potential of chemotherapy to…”
Get more information

Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial by Choy, H, DeVore, R.F, Hande, K.R, Porter, L.L, Rosenblatt, P.A, Slovis, B, Laporte, K, Shyr, Y, Johnson, D.H

“…Purpose: Docetaxel, an active agent for non-small cell lung cancer (NSCLC), has demonstrated activity as a radiosensitizer in numerous pre-clinical studies. We…”
Get full text

Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer by DEVORE, R. F, JOHNSON, D. H, MILLER, L. L, CRAWFORD, J, GARST, J, DIMERY, I. W, ECKARDT, J, ECKHARDT, S. G, ELFRING, G. L, SCHAAF, L. J, HANOVER, C. K

“…To evaluate the antitumor efficacy and safety of a combination of irinotecan (CPT-11) and cisplatin in patients with inoperable non-small-cell lung cancer…”
Get full text

Phase I study of the antineovascularization drug CM101 by DEVORE, R. F, HELLERQVIST, C. G, YORK, G. E, ZHANG, M.-H, JOHNSON, D. H, WAKEFIELD, G. B, WAMIL, B. D, THURMAN, G. B, MINTON, P. A, SUNDELL, H. W, YAN, H.-P, CARTER, C. E, WANG, Y.-F

“…CM101 is a bacterial polysaccharide that induces neovascular inflammation in malignant tumors. Fifteen patients with refractory malignancies received CM101…”
Get full text

Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46 by Johnson, D H, Paul, D M, Hande, K R, DeVore, 3rd, R F

“…Based on their good activity and minimal toxicity in non-small cell lung cancer and other cancers, we initiated a phase II trial of carboplatin plus paclitaxel…”
Get more information

Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis by CORBETT, A. H, DEVORE, R. F, OSHEROFF, N

“…The catalytic activity of topoisomerase II is stimulated approximately 2-3-fold following phosphorylation by casein kinase II (Ackerman, P., Glover, C. V. C.,…”
Get full text

Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials by DeVore, 3rd, R F, Jagasia, M, Johnson, D H

“…Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion)…”
Get more information

Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer by Choy, H, DeVore, 3rd, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, LaPorte, K, Johnson, D H

“…We conducted a prospective phase II study to determine the response rate, toxicity profile, and survival rate among patients with locally advanced unresectable…”
Get more information

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial by Johnson, D H, Paul, D M, Hande, K R, Shyr, Y, Blanke, C, Murphy, B, Lewis, M, De Vore, 3rd, R F

“…Studies conducted by the Eastern Cooperative Oncology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year…”
Get more information

Weekly Irinotecan and Cisplatin in Advanced Non-Small Cell Lung Cancer: A Multicenter Phase II Study by JAGASIA, Madan H, LANGER, Corey J, JOHNSON, David H, YUNUS, Furhan, RODGERS, John S, SCHLABACH, Larry L, COHEN, Alan G, SHYR, Yu, CARBONE, David P, DEVORE, Russell F

“…The combination of weekly irinotecan (CPT-11) and monthly cisplatin has shown promising activity in advanced non-small cell lung cancer (NSCLC) in previous…”
Get full text

Phosphorylation of topoisomerase II by casein kinase II and protein kinase C : effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide by DE VORE, R. F, CORBETT, A. H, OSHEROFF, N

“…The effects of serine phosphorylation on the DNA cleavage/religation equilibrium of topoisomerase II and the sensitivity of the enzyme to antineoplastic drugs…”
Get full text

A Phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy by DOWELL, Jonathan E, JOHNSON, David H, ROGERS, John S, SHYR, Yu, MCCULLOUGH, Nancy, KROZELY, Peggy, DEVORE, Russell F

“…To test the efficacy and safety of the novel antitumor agent MGI-114 (NSC 683863) in patients with advanced non-small cell lung cancer (NSCLC) previously…”
Get full text

A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma by Rothenberg, Mace L., Cox, John V., DeVore, Russell F., Hainsworth, John D., Pazdur, Richard, Rivkin, Saul E., Macdonald, John S., Geyer, Charles E., Sandbach, John, Wolf, Daniel L., Mohrland, J. Scott, Elfring, Gary L., Miller, Langdon L., Von Hoff, Daniel D.

“…BACKGROUND This multicenter, Phase II trial was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT‐11) in patients with metastatic…”
Get full text

Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC by Choy, H, Chakravarthy, A, Devore, 3rd, R F, Jagasia, M, Hande, K R, Roberts, J R, Johnson, D H, Yunus, F

“…In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its…”
Get more information

Pharmacodynamic Profile of Prolonged Etoposide Administration in Patients with Small Cell Lung Cancer and Non-Hodgkin's Lymphoma by Higa, Gerald M., Sarkar, Mohamadi A., DeVore, Russell F.

“…Study Objective. To determine whether therapeutic drug monitoring can enhance administration of etoposide in patients with drug‐responsive neoplasms. Design…”
Get full text

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial by WAMIL, B. D, THURMAN, G. B, SUNDELL, H. W, DEVORE, R. F, WAKEFIELD, G, JOHNSON, D. H, WANG, Y.-F, HELLERQVIST, C. G

Get full text

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer by JOHNSON, David H, FEHRENBACHER, Louis, HOLMGREN, Eric, KABBINAVAR, Fairooz, NOVOTNY, William F, HERBST, Roy S, NEMUNAITIS, John J, JABLON, David M, LANGER, Corey J, DEVORE, Russell F, GAUDREAULT, Jacques, DAMICO, Lisa A

“…To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. In a…”
Get full text